{"id":"aklief","rwe":[{"pmid":"38294764","year":"2024","title":"Drugs for acne.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"35100239","year":"2021","title":"Clascoterone cream (Winlevi) for acne.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"34554664","year":"2006","title":"Trifarotene.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"33443492","year":"2020","title":"Drugs for acne.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"33064433","year":"2020","title":"Trifarotene (Aklief) for the Treatment of Acne.","finding":"","journal":"American family physician","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Teva Pharmaceuticals USA","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Application site irritation","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Sunburn","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Application site pruritus","drugRate":"2.4%","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Scaling","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Dryness","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Application site pain","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Application site dryness","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Application site discoloration","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Application site rash","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Application site swelling","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Application site erosion","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Acne","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Dermatitis allergic","drugRate":"0.5%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":["Trifarotene 0.005 % Topical Cream"],"company":"Teva Pharmaceuticals USA","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AKLIEF®","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:08:38.017566+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:08:43.549382+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AKLIEF®","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:08:43.927046+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Retinoic acid receptor gamma agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:44.979547+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3707313/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:44.632664+00:00"}},"allNames":["aklief®"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Retinoic acid receptor alpha, Retinoic acid receptor beta, Retinoic acid receptor gamma","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Aklief's mechanism of action is not well-documented, but it is believed to involve the inhibition of a specific enzyme or receptor, leading to changes in cellular signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=aklief%C2%AE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aklief®","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:21:41.467513","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:46.445652+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"aklief®","indications":{"approved":[{"name":"Acne vulgaris","diseaseId":"acne-vulgaris","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06733402","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-06-20","conditions":["Acne Vulgaris"],"enrollment":1000,"completionDate":"2024-11-09"},{"nctId":"NCT05550337","phase":"PHASE3","title":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2022-09-19","conditions":["Acne Vulgaris"],"enrollment":807,"completionDate":"2023-05-09"},{"nctId":"NCT04856904","phase":"PHASE4","title":"Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2021-05-28","conditions":["Acne Vulgaris"],"enrollment":121,"completionDate":"2023-06-30"},{"nctId":"NCT06063473","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-02-22","conditions":["Acne Vulgaris"],"enrollment":762,"completionDate":"2023-07-13"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL3707313"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Teva Pharmaceuticals USA","relationship":"Original Developer"}],"publicationCount":10,"therapeuticAreas":["Dermatology"],"biosimilarFilings":[],"originalDeveloper":"Teva Pharmaceuticals USA","recentPublications":[{"date":"2024 Feb 5","pmid":"38294764","title":"Drugs for acne.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2021 Dec 27","pmid":"35100239","title":"Clascoterone cream (Winlevi) for acne.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2006","pmid":"34554664","title":"Trifarotene.","journal":""},{"date":"2020 Nov 30","pmid":"33443492","title":"Drugs for acne.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2020 Oct 15","pmid":"33064433","title":"Trifarotene (Aklief) for the Treatment of Acne.","journal":"American family physician"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"AKLIEF®","companyName":"Teva Pharmaceuticals USA","companyId":"teva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:46.445652+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}